Senior Director – Translational Sciences; Solid Tumor

IGI, Inc. is a global, fully integrated clinical-stage biotechnology company focused on developing innovative biologics in oncology. Headquartered in New York, NY, IGI is advancing a robust pipeline of novel, first-in-class Multispecifics™ aimed at addressing complex diseases and treating patients holistically. Powered by its proprietary BEAT® technology platform, IGI is committed to delivering breakthrough, curative therapies to improve and extend the lives of patients battling hematological malignancies and solid tumors.

For more information, visit

IGI is an equal opportunity employer, and all qualified applicants will receive consideration for employment without regard to race, color, age, religion, height, weight, sex, national origin, sexual orientation, gender identity, disability status, or any other characteristic protected by law.

Daring to imagine a world where a cure is possible. Moving beyond hope, with therapies that will forever transform medicine and lives.

To co-create innovative treatment solutions that make healthier living possible.

• Designation:
  Senior Director – Translational Sciences, Solid Tumor
• Business Unit:
  Clinical Development
• Location:
  
  NYC
• Reporting to:
  Chief Medical Officer.

An accomplished Senior Director of Translational Sciences with deep expertise in solid tumor oncology to lead our translational strategy from discovery through clinical development. This role bridges preclinical research and clinical application, driving biomarker development, patient stratification, and mechanistic insights to accelerate therapeutic innovation.

• Define and execute translational strategies for solid tumor programs across the pipeline.
• Collaborate with discovery, clinical, regulatory, and commercial teams to align translational goals with program milestones.

• Lead identification, validation, and implementation of predictive, pharmacodynamic, and prognostic biomarkers.
• Oversee development of companion diagnostics in partnership with external vendors and internal stakeholders.

• Design and support early-phase clinical trials with robust translational endpoints.
• Interpret clinical biomarker data to inform patient selection and dose optimization.

• Stay abreast of emerging technologies and trends in tumor biology, immuno-oncology, and precision medicine.
• Foster external collaborations with academic institutions, consortia, and CROs.

PhD, MD, or MD/PhD in oncology, molecular biology, immunology, or related field

10+ years of industry experience in translational sciences, with a strong focus on solid tumors.

• Proven track record of biomarker strategy development and clinical trial support.
• Deep understanding of tumor microenvironment, resistance mechanisms, and molecular profiling.
• Experience with regulatory submissions and companion diagnostic development.
• Strong leadership, communication, and cross-functional collaboration skills.
• Experience in immuno-oncology or targeted therapies.
• Familiarity with high-dimensional data (e.g., NGS, proteomics, single-cell analysis).
• Prior involvement in IND-enabling studies and regulatory interactions.